Insider Purchases: Inside the Buy
Tag: featured-home
🧬 Annexon, Part 2: The $300,000 Guillain-Barré Cost Matrix and the Pipeline Fuse
Delve into the high-stakes financial and clinical reality of Guillain-Barré Syndrome (GBS)—a devastating neurological emergency carrying a brutal $300,000 cost of standard care. In Part 2 of our Annexon Biosciences (NASDAQ: ANNX) deep dive, we audit how their lead late-stage asset, Tanruprubart, targets C1q neuroinflammation at the source to completely upend healthcare economics, transform patient outcomes, and detonate an 11-day short squeeze trap.
1 comment
|
TTD Stock Analysis 2026: Jeff Green’s $148M Bet — Is The Trade Desk the Ultimate “Buy the Dip” Play?
The Trade Desk just got the loudest kind of bullish signal: the founder-CEO bought $148M of his own stock after an 80%+ drawdown. Institutions are stacked, shorts are circling, and valuation has finally cooled from “bubble” to “business.” The question now: is TTD a generational dip… or a beautiful trap?
Apple CEO & Nike Director Tim Cook Buys Shares: Is NKE Ready to Sprint?
Nike is down nearly 70% from its peak — but insiders are stepping in. When Apple CEO and Nike director Tim Cook buys nearly $3 million worth of shares, it raises an interesting question: is the swoosh warming up for a comeback sprint?
Ex-Morgan Stanley CEO Gorman Buys Disney: Time For Wonderland — or Better Questions?
Ex-Morgan Stanley CEO James Gorman just bought Disney stock — and institutions are quietly increasing exposure. Shorts are gone, cash flow is up, buybacks are back. Is the magic really returning? 🎬✨
Sweetgreen Update: When the CEO Buys the Salad Dip
Sweetgreen (SG) just delivered a wild mix of insider buying, lowered guidance, widening losses, and surprising institutional support. With the CEO buying $1M+ of stock at the lows and valuation at historic discounts, the setup is intriguing — but still risky. Here’s the full FUNanc1al breakdown.